Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Lincoln Pharmaceuticals Ltd’s stock price declined to a fresh 52-week low of Rs.439.95 on 28 Jan 2026, marking a significant downturn amid broader market gains. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its recent financial performance and valuation metrics.

Lincoln Pharmaceuticals Ltd’s shares declined to a fresh 52-week low of Rs.442.85 on 27 Jan 2026, marking a significant milestone in the stock’s recent performance. The pharmaceutical company’s stock has been under pressure, reflecting a combination of subdued financial results and broader sector dynamics.

Lincoln Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Lincoln Pharmaceuticals Ltd has touched a fresh 52-week low of Rs.453.05 today, marking a significant decline amid a sustained downward trajectory. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and market sentiment.

Lincoln Pharmaceuticals Ltd’s shares declined to a fresh 52-week low of Rs.454.55 on 20 Jan 2026, marking a significant downturn amid broader market fluctuations and company-specific performance concerns.

Lincoln Pharmaceuticals Ltd’s shares declined to a fresh 52-week low of Rs.465.25 on 19 Jan 2026, marking a significant downturn amid broader market weakness and company-specific performance concerns.

Lincoln Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Lincoln Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 January 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.

Lincoln Pharmaceuticals has reached a new 52-week low, with its stock price touching Rs.466 today. This marks a significant decline amid broader market gains, as the stock underperformed its sector and reversed a short-term upward trend.

Lincoln Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a backdrop of subdued financial performance and challenging market conditions.

Lincoln Pharmaceuticals has touched a new 52-week low of Rs.466.4, marking a significant decline in its stock price amid broader market movements and company-specific performance trends.

Lincoln Pharmaceuticals has reached a new 52-week low of Rs.470.15, marking a significant decline amid a broader market downturn. The stock has experienced a sustained downward trend over the past four days, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Lincoln Pharmaceuticals has reached a new 52-week low of Rs.481, marking a significant decline in its stock price amid a broader market environment where the Sensex has shown mixed signals. The stock’s recent performance reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Lincoln Pharmaceuticals has reached a new 52-week low of Rs.481, marking a significant decline in its stock price amid a broader market environment where the Sensex trades near its yearly highs. The stock has experienced a three-day consecutive fall, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Lincoln Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a backdrop of subdued financial performance and challenging market conditions, prompting a reassessment of the company’s standing within its sector.

Lincoln Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition from mildly bearish to bearish technical trends, underscoring a nuanced market assessment for this Pharmaceuticals & Biotechnology sector stock.

Lincoln Pharmaceuticals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators across multiple timeframes. Recent market data reveals a mild transition in trend dynamics, with key technical parameters signalling a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.